confidential trade secrets or commercial property such as patentable material,
and personal information concerning individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.

Name of Committee: National Deafness and
Other Communication Disorders Advisory
Council.

Date: September 12, 2013.

Closed: 8:30 a.m. to 10:00 a.m.

Agenda: To review and evaluate grant
applications.

Place: National Institutes of Health,
Building 31, Conference Room 6, 31 Center
Drive, Bethesda, MD 20892.

Open: 10:00 a.m. to 1:55 p.m.

Agenda: Staff reports on divisional,
programmatic, and special activities.

Contact Person: Craig A. Jordan, Ph.D.,
Director, Division of Extramural Activities,
NIDCD, NIH, Room 8345, MSC 9670, 6001
Executive Blvd., Bethesda, MD 20892–9670,
301–496–8693, jordanc@niddc.nih.gov.

Any interested person may file written
commits with the committee by forwarding
the statement to the Contact Person listed
on this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.

In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
 campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.

Information is also available on the
Institute’s/Center’s home page:
www.niddc.nih.gov/about/groups/ndc dac/
nndcdac.htm, where an agenda and any
additional information for the meeting will
be posted when available.

(Catalogue of Federal Domestic Assistance
Program Nos. 93.173, Biological Research
Related to Deafness and Communicative
Disorders, National Institutes of Health, HHS)

Dated: July 29, 2013.

Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.

[FR Doc. 2013–18585 Filed 8–1–13; 8:45 am]

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

Substance Abuse and Mental Health
Services Administration

Current List of Laboratories and
Instrumented Initial Testing Facilities
Which Meet Minimum Standards To
Engage in Urine Drug Testing for
Federal Agencies

AGENCY: Substance Abuse and Mental
Health Services Administration, HHS.

ACTION: Notice.

SUMMARY: The Department of Health and
Human Services (HHS) notifies Federal
agencies of the Laboratories and
Instrumented Initial Testing Facilities
(IITF) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines). The
Mandatory Guidelines were first
published in the Federal Register
April 1, 1988 (53 FR 11970), and
subsequently revised in the Federal
Register on June 9, 1994 (59 FR 29908);
September 30, 1997 (62 FR 51118);
April 13, 2004 (69 FR 19644); November
25, 2008 (73 FR 71858); December 10,
2008 (73 FR 75122); and on April 30,
2010 (75 FR 22809).

A notice listing all currently certified
Laboratories and Instrumented Initial
Testing Facilities (IITF) is published in the
Federal Register during the first
week of each month. If any Laboratory/
IITF’s certification is suspended or
revoked, the Laboratory/IITF will be
omitted from subsequent lists until such
time as it is restored to full certification
under the Mandatory Guidelines.

If any Laboratory/IITF has withdrawn
from the HHS National Laboratory
Certification Program (NLCP) during the
past month, it will be listed at the end
and will be omitted from the monthly
listing thereafter.

This notice is also available on the Internet at http://
www.workplace.samhsa.gov.

FOR FURTHER INFORMATION CONTACT:
Giselle Hersh, Division of Workplace
Programs, SAMHSA/CSAP, Room
7–1051, One Choke Cherry Road,
Rockville, Maryland 20857; 240–726–
2600 (voice), 240–276–2610 (fax).

SUPPLEMENTARY INFORMATION: The
Mandatory Guidelines were initially
developed in accordance with Executive
Order 12564 and section 503 of Public
Law 100–71. The “Mandatory
Guidelines for Federal Workplace Drug
Testing Programs”, as amended in the
revisions listed above, requires strict
standards that Laboratories and
Instrumented Initial Testing Facilities
(IITF) must meet in order to conduct
drug and specimen validity tests on
urine specimens for Federal agencies.

To become certified, an applicant
Laboratory/IITF must undergo three
rounds of performance testing plus an
on-site inspection. To maintain that
certification, a Laboratory/IITF must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.

Laboratories and Instrumented Initial
Testing Facilities (IITF) in the applicant
stage of certification are not to be
considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines. A Laboratory/
IITF must have its letter of certification
from HHS/SAMHSA (formerly: HHS/
NIDA) which attests that it has met
minimum standards.

In accordance with the Mandatory
Guidelines dated November 25, 2008
(73 FR 71858), the following
Laboratories and Instrumented Initial
Testing Facilities (IITF) meet the
minimum standards to conduct drug
and specimen validity tests on urine
specimens:

Instrumented Initial Testing Facilities
(IITF)

None.

Laboratories

ACL Laboratories, 8901 W. Lincoln
Ave., West Allis, WI 53227, 414–328–
7840/800–827–7016. (Formerly:
Bayshore Clinical Laboratory)

ACM Medical Laboratory, Inc., 160
Elmgrove Park, Rochester, NY 14624,
385–429–2264

Aegis Analytical Laboratories, 345 Hill
Ave., Nashville, TN 37210, 615–255–
2400. (Formerly: Aegis Sciences
Corporation, Aegis Analytical
Laboratories, Inc.)

Alere Toxicology Services, 1111 Newton
St., Gretna, LA 70053, 504–361–8989/800–
433–3823, (Formerly: Kroll
Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.)

Alere Toxicology Services, 450
Southlake Blvd., Richmond, VA
23236, 804–378–9130, (Formerly:
Kroll Laboratory Specialists, Inc.,
Scientific Testing Laboratories, Inc.;
Kroll Scientific Testing Laboratories, Inc.)

Baptist Medical Center-Toxicology
Laboratory, 11401 I–30, Little Rock,
AR 72209–7058, 501–202–2783,
(Formerly: Forensic Toxicology
Laboratory Baptist Medical Center)

Clinical Reference Lab, 8433 Quivira
Road, Lenexa, KS 66215–2802, 800–
445–6917
DOCTORS LABORATORY, INC., 2906 JULIA DRIVE, VALDOSTA, GA 31602, 229–671–2281

DRUGSCAN, INC., 200 PRECISION ROAD, SUITE 200, HORSHAM, PA 19044, 800–235–4890

ELSOHY LABORATORIES, INC., 5 INDUSTRIAL PARK DRIVE, OXFORD, MS 38655, 662–236–2609

FORTES LABORATORIES, INC., 25749 SW CANYON CREEK ROAD, SUITE 600, WILSONVILLE, OR 97070, 503–486–1023


LABORATORY CORPORATION OF AMERICA HOLDINGS, 1020 MAIN STREET, SOUTH BEND, IN 46601, 574–234–4126 x1276

LABONE, INC. D/B/A QUEST DIAGNOSTICS, 10101 RENNER BLVD., LENEXA, KS 66219, 913–888–3927/800–873–8845, (FORMERLY: QUEST DIAGNOSTICS INCORPORATED; LABONE, INC.; CENTER FOR LABORATORY SERVICES, A DIVISION OF LABONE, INC.)

MEDTIX LABORATORIES, INC., 402 W. COUNTY ROAD D, ST. PAUL, MN 55112, 651–636–7428/800–832–3244

METROLAB–LEGACY LABORATORY SERVICES, 1225 NE 2ND AVE., PORTLAND, OR 97232, 503–413–5295/800–950–5295

MINNEAPOLIS VETERANS AFFAIRS MEDICAL CENTER, FORENSIC TOXICOLOGY LABORATORY, 1 VETERANS DRIVE, MINNEAPOLIS, MN 55417, 612–725–2088

NATIONAL TOXICOLOGY LABORATORIES, INC., 1100 CALIFORNIA AVE., BAKERSFIELD, CA 93304, 661–322–4250/800–350–3515

ONE SOURCE TOXICOLOGY LABORATORY, INC., 1213 GENOA–RED BLUFF, PASADENA, TX 77504, 888–747–3774, (FORMERLY: UNIVERSITY OF TEXAS MEDICAL BRANCH, CLINICAL CHEMISTRY DIVISION; UTMB PATHOLOGY–TOXICOLOGY LABORATORY)

PACIFIC TOXICOLOGY LABORATORIES, 9348 DEDATO AVE., CHATSWORTH, CA 91311, 800–328–6942, (FORMERLY: CENTINELA HOSPITAL AIRPORT TOXICOLOGY LABORATORY)

PATHOLOGY ASSOCIATES MEDICAL LABORATORIES, 110 WEST CLIFF DR., SPOKANE, WA 99204, 509–755–8991/800–541–7981 x177

PHAMATECH, INC., 10151 BARNES CANYON ROAD, SAN DIEGO, CA 92111, 858–643–5555


QUEST DIAGNOSTICS INCORPORATED, 1777 MONTRAL CIRCLE, TUCKER, GA 30084, 770–729–6432, (FORMERLY: SMITHKLINE BEECHAM CLINICAL LABORATORIES; SMITHKLINE BIO–SCIENCE LABORATORIES)


QUEST DIAGNOSTICS INCORPORATED, 8401 FALLBROOK AVE., WEST HILLS, CA 91304, 818–737–6370, (FORMERLY: SMITHKLINE BEECHAM CLINICAL LABORATORIES)

REDWOOD TOXICOLOGY LABORATORY, 3650 WESTWIND BLVD., SANTA ROSA, CA 95403, 707–570–4434

SOUTH BEND MEDICAL FOUNDATION, INC., 530 N. LAFAYETTE BLVD., SOUTH BEND, IN 46601, 574–234–4176 x1276

SOUTHWEST LABORATORY SERVICES, 4625 E. COTTON CENTER BOULEVARD, SUITE 177, PHOENIX, AZ 85040, 602–438–8507/800–279–0027

STERLING REFERENCE LABORATORIES, 2617 EAST L STREET, TACOMA, WASHINGTON 98421, 800–442–0438

TOXICOLOGY & DRUG MONITORING LABORATORY, UNIVERSITY OF MISSOURI HOSPITAL & CLINICS, 301 BUSINESS LOOP 70 WEST, SUITE 208, COLUMBIA, MO 65203, 573–882–1273

U.S. ARMY FORENSIC TOXICOLOGY DRUG TESTING LABORATORY, 2490 WILSON ST., FORT GEORGE G. MEADE, MD 20755–5235, 301–677–7085

The Standards Council of Canada (SCC) voted to end its Laboratory Accreditation Program for Substance Abuse (LAPSA) effective May 12, 1998. Laboratories certified through that program were accredited to conduct forensic urine drug testing as required by U.S. Department of Transportation (DOT) regulations. As of that date, the certification of those accredited Canadian laboratories will continue under DOT authority. The responsibility for conducting quarterly performance testing plus periodic on-site inspections of those LAPSA– accredited laboratories was transferred to the U.S. HHS, with the LAPSA’s NLCP contractor continuing to have an active role in the performance testing and laboratory inspection processes. Other Canadian laboratories wishing to be considered for the NLCP may apply directly to the NLCP contractor just as U.S. laboratories do.

Upon finding a Canadian laboratory to be qualified, HHS will recommend that DOT certify the laboratory (Federal Register, July 16, 1996) as meeting the minimum standards of the Mandatory Guidelines published in the Federal Register on April 30, 2010 (75 FR 22809). After receiving DOT certification, the laboratory will be included in the monthly list of HHS–certified laboratories and be available for selection as a partner for DOT testing.

Janine Denis Cook, Chemist, Division of Workplace Programs, Center for Substance Abuse Prevention, SAMHSA.

[FR Doc. 2013–18628 Filed 8–1–13; 8:45 am]

BILLING CODE 4160–20–P

DEPARTMENT OF HOMELAND SECURITY

[Docket No. DHS–2013–0047]

Agency Information Collection Activities: Submission for Review; Information Collection Request for the Department of Homeland Security (DHS), Science and Technology, CyberForensics Electronic Technology Clearinghouse (CyberFETCH) Program

AGENCY: Science and Technology Directorate, DHS.

ACTION: 60-day Notice and request for comment.

SUMMARY: The Department of Homeland Security (DHS) Science & Technology (S&T) Directorate invites the general public to comment on data collection forms for the CyberForensics Electronic Technology Clearinghouse (CyberFETCH) program, and is a revision of a previously approved collection. CyberFETCH is responsible for providing a collaborative environment to upload information, best practices and lessons learned within a secure collaborative environment. In order for a user to access this clearinghouse, he/she must complete a registration form to establish a user account. The information collected is used by the DHS S&T CyberFETCH program to determine the authenticity and suitability of the practitioner requesting access. Once approved, users will utilize the collaborative environment to upload documents/resources, exchange